Partner

Aisha has 18+ years of professional experience, both in the public and private sector with 12 years of experience in public and investor relations in the biotech industry. She has closely collaborated with CEO’s and senior executives on the execution and completion of multiple private and public financing transactions raising over $600 million. 

Prior to setting up her own consultancy, she was the Director Corporate Affairs of NorthSea Therapeutics (NST), a clinical-stage biotech company where she was responsible for the development and implementation of the pre- and post IPO communications and investor relations program. Before joining NST, she was Director Corporate & Legal Affairs of G7 Therapeutics AG, a GPCR-company based in Zurich, Switzerland. As part of the leadership team, she was directly involved in the acquisition of the company by Heptares Therapeutics for CHF 12m in December 2016. 

From 2009 to 2016 she served as Head of Investor relations and acting Corporate Secretary of the Nasdaq listed company uniQure N.V. During her time at uniQure she has led the implementation of investor relations, governance, media and communications programs for the IPO, supported in a crucial company transition involving a delisting from the EURONEXT Stock Exchange, a subsequent listing on NASDAQ, M&A and other major financial transactions.

Aisha received a Bachelor of Law from Amsterdam University; combined with an MBA at Rotterdam School of Management, Erasmus University. 

Partner

Ken Rea is a Partner at Koralis Corporate. He one of Europe’s top presentation and communication skills trainers. Throughout Europe, Professor Ken Rea has profoundly influenced over 2,000 leaders in business and industry, extending up to the CEO level. His impactful contributions span diverse organizations, such as BBC, BT, IBM, KLM, Lloyds of London, Macquarie, Metropolitan Police, Moët Hennessy, Morgan Stanley, Nationwide, NATO, NatWest, Nokia, Orange, Royal Bank of Scotland, Sainsbury's, UniQure, Vivoryon andMerck &Co.

Commencing his career in advertising, crafting TV commercials in New Zealand, Ken transitioned to the world of theatre, excelling as an actor, director, and teacher. In conjunction with his corporate endeavors, he has held the esteemed position of Professor of Theatre at the renowned Guildhall School of Music & Drama. Here, he has imparted his expertise to some of Britain’s foremost actors and film stars, including Ewan McGregor, Damian Lewis, Michelle Dockery, Lily James, Orlando Bloom, and Daniel Craig. Ken has also presided over numerous European conferences.

As a dynamic public speaker, Ken has delivered compelling presentations to large audiences in the realms of business, education, and the arts, occasionally addressing gatherings of over 1,000 individuals. Notably, he has contributed as a feature writer for The Times and served as a theatre critic for The Guardian for 15 years.

Ken's theatrical works, such as The Brave Magicians of Mangalore and Voyagers, have been successfully produced in Britain. His adaptations in London include the Swedish classic, Pippi Longstocking, and the Italian Renaissance comedy, The Deceived.

His latest book, The Outstanding Actor: Seven Keys to Success, stands as a source of inspiration for both actors and business leaders alike. Currently, Ken is engaged in research on charismatic leadership in collaboration with Imperial College Business School.

Advisor

Serving as a business advisor to Koralis Corporate, Mr. Hendriks brings over 25 years of experience in strategic and corporate finance in complex, international and matrixed environments across a variety of industries. During his career he completed many financing rounds, raising over $650 million through private financing, strategic partnerships, a total of three NASDAQ IPO’s and several follow-on’s in the biotech space.

Robert Hendriks currently serves as the Vice President, Finance, and member of the leadership team of Molecular Partners, a SIX and Nasdaq listed, clinical-stage biopharmaceutical company (Zurich, Switzerland). He played a pivotal role in the company’s recent listing on the Nasdaq stock exchange in June 2021.

Prior to joining Molecular Partners, he managed Verona Pharma’s (London, UK) 90 million-dollar IPO on the Nasdaq stock exchange where he was a key driver in the IFRS financials presented in the SEC registration statement and he successfully initiated the implementation of a SOX framework for the company to meet its SEC reporting obligations. 

Before joining Verona Pharma, he was the Senior Director Global Finance and acting CFO of uniQure NV, another Nasdaq listed European biotech company, where he led the companies first filing of the 20-F with the SEC. During his tenure, the IPO and the follow-on financing generated a total of 168 million USD in equity financing. Furthermore, he was directly involved in a cross-border M&A transaction that resulted in the acquisition of a German based spin-off that paved the way for a 2.5 billion USD partnership with Bristol Myers Squibb. 

Mr. Hendriks holds a degree in business administration from the Erasmus University in Rotterdam, Netherlands, and has attended executive education programs at Wharton School of the University of Pennsylvania and Darden School of Business at the University of Virginia.Throughout his career he has conducted business in Dutch, English, German and French. 

Advisor

Serving as a business advisor to Koralis Corporate, he brings over 30 years of experience in the field of strategy, finance and corporate governance. As a board member with a financial background he participated actively in fundraising - debt and equity- for publicly-traded and privately-held companies in both Europe and the US.  

Ferdinand Verdonck currently serves as a director of a privately held IT company in Belgium. Since 2003 he has been on the board of several companies, mainly in Financial Services and Biotech industry.  In recent years he was director of Virtus Funds (US) and J.P. Morgan European Investment Trust (UK), director of Groupe SNEF in France, and director and chairman of biotechnology companies: uniQure N.V. in the Netherlands, Movetis and Galapagos in Belgium and Affimed in Germany. 

He has previously served as chairman of Banco Urquijo and of Nasdaq Europe and as a director of Dictaphone Corporation. From 1992 to 2003, he was the managing director of Almanij NV, a financial services company, based in Belgium which has since merged with, its main subsidiary, KBC. 

Mr. Verdonck holds a law degree from KU Leuven and degrees in economics from KU Leuven and the University of Chicago. Throughout his career he has conducted business in Dutch, French, English, Spanish and German.